LENZ Therapeutics (LENZ) News Today $29.53 +0.82 (+2.86%) Closing price 04:00 PM EasternExtended Trading$29.94 +0.40 (+1.37%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decisionMay 29 at 4:37 AM | uk.investing.comRafferty Asset Management LLC Purchases Shares of 17,716 LENZ Therapeutics, Inc. (NASDAQ:LENZ)Rafferty Asset Management LLC purchased a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 17,716 shares of the company's stock, valuedMay 25, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Northern Trust Corp raised its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 7.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,288 shares of the company's stock after purchasing an additionaMay 25, 2025 | marketbeat.comDelta Investment Management LLC Takes $555,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Delta Investment Management LLC bought a new position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 19,241 shares of the company's stock, valued at approximately $555,000. DeltaMay 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Reduces Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Point72 Asset Management L.P. trimmed its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 9.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 783,921 shares of the company's stock after selling 81,021May 19, 2025 | marketbeat.comParadigm Biocapital Advisors LP Purchases New Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Paradigm Biocapital Advisors LP purchased a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 770,455 shares of the company's stock, valMay 16, 2025 | marketbeat.comGranahan Investment Management LLC Buys Shares of 51,842 LENZ Therapeutics, Inc. (NASDAQ:LENZ)Granahan Investment Management LLC purchased a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 51,842 shares of the companMay 13, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Acquires 36,582 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)The Manufacturers Life Insurance Company grew its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 116.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 67,891 shares of the company's stock after acqMay 13, 2025 | marketbeat.comLeerink Partnrs Analysts Raise Earnings Estimates for LENZLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Research analysts at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now expects that theMay 13, 2025 | marketbeat.comHC Wainwright Issues Negative Estimate for LENZ EarningsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for shares of LENZ Therapeutics in a report issued on Thursday, May 8th. HC Wainwright analyst M. Caufield now expects that the company will post earnings perMay 13, 2025 | marketbeat.comQ2 EPS Forecast for LENZ Therapeutics Raised by AnalystLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - William Blair lifted their Q2 2025 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a note issued to investors on Thursday, May 8th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earningMay 13, 2025 | marketbeat.comLENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatmentMay 13, 2025 | msn.comLENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comHC Wainwright Reiterates "Buy" Rating for LENZ Therapeutics (NASDAQ:LENZ)HC Wainwright reiterated a "buy" rating and set a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday.May 10, 2025 | marketbeat.comEarnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation driveMay 9, 2025 | uk.investing.comLENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast AsiaMay 9, 2025 | globenewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of "Buy" by BrokeragesShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned a consensus recommendation of "Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned aMay 9, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by Alyeska Investment Group L.P.Alyeska Investment Group L.P. lifted its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 16.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 142,113 shares of the company's stock aftMay 8, 2025 | marketbeat.comBarclays PLC Increases Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Barclays PLC increased its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 82.6% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 30,057 shares of the company's stock after buying an additional 13,594 shares during the quarter. Barclays PLCMay 8, 2025 | marketbeat.comLENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 7, 2025 | globenewswire.comLENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care ConferenceMay 6, 2025 | globenewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD boosted its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 83.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 822,957 shares of the company'May 4, 2025 | marketbeat.comRenaissance Technologies LLC Sells 23,900 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)Renaissance Technologies LLC lowered its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 48.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,366 shares of the company's stock afteMay 4, 2025 | marketbeat.comSamsara BioCapital LLC Lowers Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Samsara BioCapital LLC lessened its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 18.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 986,981 shares of the company's stock after selling 221,492 shares during theMay 2, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Position Lessened by Boothbay Fund Management LLCBoothbay Fund Management LLC decreased its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 26.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,746 shares of the company's stocMay 1, 2025 | marketbeat.comLENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025April 30, 2025 | globenewswire.comRock Springs Capital Management LP Acquires New Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Rock Springs Capital Management LP purchased a new position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,305 shares of the company's stockApril 23, 2025 | marketbeat.comLENZ Therapeutics' (LENZ) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research note on Wednesday.April 18, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 908 Devices (MASS), LENZ Therapeutics (LENZ) and Johnson & Johnson (JNJ)April 17, 2025 | markets.businessinsider.comLENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Should You Buy?LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Here's WhyApril 17, 2025 | marketbeat.comBank of America Securities Keeps Their Buy Rating on LENZ Therapeutics (LENZ)April 17, 2025 | markets.businessinsider.comLENZ Therapeutics (LENZ) Receives a Buy from TD CowenApril 17, 2025 | markets.businessinsider.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 8.3% - Still a Buy?LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 8.3% - Time to Buy?April 16, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Piper SandlerPiper Sandler started coverage on LENZ Therapeutics in a report on Monday. They issued an "overweight" rating and a $51.00 price target for the company.April 16, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. boosted its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 5.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,178,447 shares of the company's stockApril 15, 2025 | marketbeat.comLenz Therapeutics assumed with an Overweight at Piper SandlerApril 14, 2025 | markets.businessinsider.comLENZ Therapeutics (LENZ) Receives a Buy from Piper SandlerApril 14, 2025 | markets.businessinsider.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Buy" by BrokeragesShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have received a consensus rating of "Buy" from the eight research firms that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy ratApril 14, 2025 | marketbeat.comnew option listings on April 9thApril 9, 2025 | markets.businessinsider.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.5% - Here's What HappenedLENZ Therapeutics (NASDAQ:LENZ) Trading Down 8.5% - Time to Sell?April 9, 2025 | marketbeat.comLENZ Therapeutics: Freedom From Reading GlassesApril 7, 2025 | seekingalpha.comLenz Therapeutics files $500M mixed securities shelfApril 5, 2025 | markets.businessinsider.comLenz Therapeutics files to sell 13.07M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comLENZ Therapeutics files to sell 13M shares of common stock for holdersApril 4, 2025 | msn.comLENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - What's Next?LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Here's What HappenedApril 4, 2025 | marketbeat.comClimb Bio Appoints Seasoned Biotech Leaders to Board of DirectorsApril 1, 2025 | markets.businessinsider.com18,900 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by Swiss National BankSwiss National Bank acquired a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 18,900 shares of the company's stock, valued at approximatelyMarch 31, 2025 | marketbeat.comLENZ Therapeutics Stock Is Attractive Before PDUFAMarch 27, 2025 | seekingalpha.comBrokers Issue Forecasts for LENZ Q2 EarningsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for LENZ Therapeutics in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst M. Caufield anticipates that the company will earn ($0.60) perMarch 24, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for LENZ Q1 Earnings?LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for LENZ Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Leerink Partnrs analyst M. Goodman anticipates thMarch 24, 2025 | marketbeat.com Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address LENZ Media Mentions By Week LENZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LENZ News Sentiment▼1.210.87▲Average Medical News Sentiment LENZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LENZ Articles This Week▼43▲LENZ Articles Average Week Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MTSR News Today VKTX News Today AKRO News Today ALVO News Today CPRX News Today CRNX News Today SRRK News Today MRUS News Today MOR News Today PTGX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LENZ) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
